Journal article
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Abstract
OBJECTIVE: To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA).
METHODS: In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double-blinded randomization to continue to receive abatacept monthly or …
Authors
Langford CA; Cuthbertson D; Ytterberg SR; Khalidi N; Monach PA; Carette S; Seo P; Moreland LW; Weisman M; Koening CL
Journal
Arthritis & Rheumatology, Vol. 69, No. 4, pp. 837–845
Publisher
Wiley
Publication Date
4 2017
DOI
10.1002/art.40044
ISSN
2326-5191